Antiviral agent 83 

Antiviral agent 83 is a boronic acid-modified Neocryptolepine (HY-E70250) derivative and is an anti-HPV agent. Antiviral agent 83 bind to the viral capsid protein and/or envelope protein, inducing conformational changes that effectively obstruct the interaction between the virus and host cell receptors. Antiviral agent 83 exhibits inhibitory activity against multiple high-risk HPV strains. Antiviral agent 83 inhibits HPV infection in vitro and in vaginal tract in vivo^[1].

Antiviral agent 83 (Compound 13B) (10 μM; 48 h) inhibits HPV-16 PsVs infection in HeLa cells with high efficacy and low cytotoxicity, the virus inhibition rate is 83.33%, and the cytotoxicity is 5.71%^[1].
Antiviral agent 83 (48 h) inhibits HPV-16 PsVs with an IC₅₀ of 8.84 μM and exhibits low cytotoxicity in HeLa and VK2/E6E7 cells, with CC₅₀ values of 62.14 μM and 89.08 μM, respectively, resulting in high selectivity indices of 7.03 and 10.08^[1].
Antiviral agent 83 (0.625-10 μM; 48 h) potently inhibits infection by high-risk HPV-16, -18, -31, and -45 PsVs in HeLa cells with IC₅₀ values ranging from 7.80 to 12.45 μM^[1].
Antiviral agent 83 (5-20 μM; 1 h or 4 h preincubation; 48 h total incubation) directly inactivates HPV-45 PsVs in a dose- and time-dependent manner, with increased inhibition observed with longer pre-treatment durations^[1].
Antiviral agent 83 (10 μM; 4 h) disrupts the morphological integrity of HPV-45 PsVs when incubated at 10 μM for 4 h^[1].
Antiviral agent 83 binds specifically and with high affinity to HPV-16 L1 protein, with a K_d of 93.6 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Antiviral agent 83 (20-40 μM; intravaginal; daily; 3 days) provides almost complete protection against genital HPV-16 PsV infection in nude mice, with statistically significant suppression of viral signal^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

472.35

C₂₉H₂₅BN₄O₂

CN1C2=NC3=CC=CC=C3C2=C(NC4=CC(NCC5=CC(B(O)O)=CC=C5)=CC=C4)C6=C1C=CC=C6

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zhang K, et al. Design, synthesis, and anti-HPV activity evaluation of neocryptolepine derivatives with boronic acid modification. Eur J Med Chem. 2026;312:118850.